English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 21 December 2020, 19:00 HKT/SGT
Share:
China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level

HONG KONG, Dec 21, 2020 - (ACN Newswire) - Morgan Stanley Capital International (MSCI) issued a report on December 17 upgrading the ESG (Environmental, Social and Governance) Rating for China Medical System Holdings Limited ("China Medical System"), a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. China Medical System's ESG Rating has been upgraded from "BBB" to "AA", surpassing 88% of companies in the global pharmaceutical industry, symbolizing that the Company has attained a level among its global peers in ESG management.

MSCI recognized China Medical System's outstanding performance in Corporate Governance, Corporate Behavior, Product Safety and Quality, Human Capital Development, and Access to Health Care, noting that the Company "Leads peers in business ethics and talent management practices". MSCI also gave a positive assessment of the Company's Corporate Behavior, "China Medical System has evidence of detailed policies on business ethics and corruption".

There are seven levels of the MSCI-ESG Rating, from the highest to the lowest are AAA, AA, A, BBB, BB, B, and CCC. Among them, companies with AA or AAA ratings are considered to be industry leaders in managing the most significant ESG risks and opportunities. This year, China Medical System's MSCI-ESG Rating has been upgraded by three levels, from BB to AA.

According to the Company, "Receiving the AA ESG Rating from MSCI reflected China Medical System's long-term focus and resource investment on ESG management and information disclosure, and affirmed the Company's compliance focus and solid business practices. In recent years, with leadership from the Board of Directors, the Company's ESG-related policies have increasingly improved, ESG practices are more standardized, and ESG management is constantly refined.

"In the future, through self-challenge and transcendence, China Medical System will continuously pursue higher corporate governance goals. The Company will continuously regard innovation as its driving force, to fulfill the unmet medical needs, and contribute to the integrated development of society, the environment, and civilization."


Topic: Rating Report Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Military Metals Enters into LOI to Acquire Two Antimony and One Tin Property in the European Union  
Oct 7, 2024 20:39 HKT/SGT
32nd Edition of Digital Transformation Summit Announced by Exito Media Concepts  
Oct 7, 2024 15:45 HKT/SGT
Unlocking India's Offshoring Advantage: Your Ultimate Guide for 2024  
Oct 7, 2024 13:00 HKT/SGT
Indonesia's Path to Society 5.0: Driving Digital Innovation at the Digital Transformation Summit  
Oct 7, 2024 10:40 HKT/SGT
JCB to offer Google Pay(TM) in Japan  
Monday, October 7, 2024 10:00:00 AM
Success at the 9th Annual REITs and Real Estate Investment Summit Asia Pacific 2024(TM): Driving Profits Through Sustainable Technology and Net Zero Imperatives  
Oct 7, 2024 09:00 HKT/SGT
Antidote Announces $100M for Community Building and User Rewards  
Oct 4, 2024 19:00 HKT/SGT
Hong Kong Films @ Busan 2024 opens tomorrow  
Oct 4, 2024 17:18 HKT/SGT
Pluk Phak Praw Rak Mae PCL (SET: OKJ) Eyes Expansion as the 'King of Organic Salad'  
Oct 4, 2024 14:00 HKT/SGT
Fujitsu highlights technologies to realize its vision of AI as a trusted assistant at CEATEC 2024  
Friday, October 4, 2024 10:03:00 AM
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575